Volume | 591,297 |
|
|||||
News | - | ||||||
Day High | 21.2999 | Low High |
|||||
Day Low | 20.67 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cassava Sciences Inc | SAVA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
20.93 | 20.67 | 21.2999 | 20.80 | 20.83 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,079 | 591,297 | $ 20.94 | $ 12,383,664 | - | 12.3202 - 45.4287 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:54:22 | formt | 193 | $ 20.80 | USD |
Cassava Sciences (SAVA) Options Flow Summary
Cassava Sciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
876.8M | 42.17M | - | 0 | -76.25M | -1.81 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cassava Sciences News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAVA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.32 | 21.60 | 20.22 | 20.90 | 529,089 | -0.52 | -2.44% |
1 Month | 23.89 | 25.46 | 19.20 | 21.58 | 886,976 | -3.09 | -12.93% |
3 Months | 21.00 | 25.46 | 12.3202 | 18.42 | 1,254,947 | -0.20 | -0.95% |
6 Months | 22.76 | 27.21 | 12.3202 | 19.67 | 1,054,019 | -1.96 | -8.61% |
1 Year | 34.76 | 45.4287 | 12.3202 | 24.40 | 1,058,423 | -13.96 | -40.16% |
3 Years | 7.67 | 146.16 | 6.70 | 50.38 | 2,911,489 | 13.13 | 171.19% |
5 Years | 1.21 | 146.16 | 1.00 | 34.63 | 2,900,452 | 19.59 | 1,619.01% |
Cassava Sciences Description
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. |